Markets, capital, and the discipline of patient investing.
RFC Capital Research publishes the independent analysis of Ruslan Averin — an investor focused on public markets, sovereign and corporate fixed income, cross-border real estate, and capital allocation across emerging and frontier markets.
No institutional mandate, no house view to defend — a working record of how one investor thinks about risk, value, and the markets most analysts avoid.
A $16 Million Revenue Miss Cost AppLovin $40 Billion
AppLovin missed Q2 2026 revenue by $16.3 million and lost up to $40.2 billion in equity value. An analysis of what the reaction actually priced.
MarketsCertara Fell 23.7% — Software Sold Into a Sector That Is Cutting
Certara missed second-quarter earnings expectations and fell 23.7%. Biosimulation software sits downstream of pharmaceutical R&D budgets.
MarketsDatadog Beat, Raised Guidance, and Fell the Most in Its History
Datadog grew revenue 36% to $1.12bn, beat on EPS and raised full-year guidance — then recorded its largest single-day decline. What the market repriced.
MarketsDaVita Beat Estimates, Reaffirmed Guidance, and Fell 18%
DaVita beat analyst estimates but reported declining revenue per treatment and rising patient care costs, and chose to reaffirm rather than raise guidance.
MarketsInsulet Cut Its Full-Year Outlook and Lost 17%
Insulet lowered its full-year 2026 revenue growth guidance and cut its US outlook, and the shares fell 17%. What a guidance cut means in medical devices.
MarketsPeloton Turned Its First Annual Profit and the Stock Fell 15%
Peloton posted its first-ever annual net profit, then guided fiscal 2027 revenue to $2.3-2.4bn — a 3.9% decline at the midpoint. Memberships fell 8%.